a Genitourinary Malignancies Branch , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Expert Opin Biol Ther. 2016 Jul;16(7):895-901. doi: 10.1517/14712598.2016.1170805. Epub 2016 Apr 8.
Over the past few years, trials evaluating immunotherapies, particularly immune checkpoint inhibitors, have revolutionized the standard model of cancer treatment, demonstrating significant antitumor responses and improved clinical outcomes across a wide array of tumors types. Yet, despite these compelling data, a major limitation has been that only a fraction of patients mount a response to single-agent immune checkpoint inhibition. However, a growing amount of preclinical and clinical data suggests that combining immune checkpoint inhibition, either with other immune checkpoint inhibitors or with therapeutic cancer vaccines, has the potential to improve the proportion of patients seeing long-term durable responses with these therapies.
We have reviewed the reported data on immune checkpoint inhibition as monotherapy and as combination therapy with other immune checkpoint inhibitors or therapeutic cancer vaccines. Data is reviewed on agents with FDA approval or breakthrough designation as of the writing of this manuscript.
Particular focus is given to the combination of immune checkpoint inhibitors and therapeutic cancer vaccines which has the potential to increase efficacy compared to single agent immune checkpoint inhibition with minimal added toxicity.
在过去的几年中，评估免疫疗法的试验，特别是免疫检查点抑制剂，已经彻底改变了癌症治疗的标准模式，在多种肿瘤类型中显示出显著的抗肿瘤反应和改善的临床结果。然而，尽管有这些令人信服的数据，但一个主要的限制是，只有一小部分患者对单一药物的免疫检查点抑制产生反应。然而，越来越多的临床前和临床数据表明，将免疫检查点抑制与其他免疫检查点抑制剂或治疗性癌症疫苗联合使用，有可能提高这些疗法看到长期持久反应的患者比例。
我们已经审查了关于免疫检查点抑制作为单一疗法以及与其他免疫检查点抑制剂或治疗性癌症疫苗联合治疗的报告数据。本研究报告撰写时，对获得 FDA 批准或突破性指定的药物进行了数据回顾。
特别关注免疫检查点抑制剂和治疗性癌症疫苗的联合应用，与单一药物免疫检查点抑制相比，这种联合应用有可能提高疗效，而毒性最小。
